An update on the current pharmacotherapy for endometrial cancer

被引：26
作者：
de Haydu, Christopher [1 ]
Black, Jonathan D. [2 ]
Schwab, Carlton L. [2 ]
English, Diana P. [2 ]
Santin, Alessandro D. [2 ]
机构：
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[2] Yale Univ, Sch Med, Gynecol Oncol Sect, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2016年 / 17卷 / 04期
关键词：
targeted therapy; endometrial cancer; chemotherapy; Adjuvant therapy; endometrial pharmacotherapy; hormone therapy; uterine cancer; PHASE-II TRIAL; PERFRINGENS ENTEROTOXIN CPE; DEPENDENT KINASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; UTERINE SEROUS CARCINOMA; PTEN EXPRESSION; MEDROXYPROGESTERONE ACETATE; ADJUVANT CHEMOTHERAPY; AKT PHOSPHORYLATION; THERAPEUTIC TARGET;
D O I：
10.1517/14656566.2016.1127351
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction: Endometrial cancer (EC) is the most common gynecologic malignancy in the developed world and is increasing in incidence. While the mainstay of treatment for EC is surgery followed by chemotherapy and/or radiation therapy, the available pharmacotherapies are rapidly and constantly evolving. Understanding these new therapies is an important part of the research and clinical care of women with EC. A review of available literature from MEDLINE (1879-2015) was conducted for the historic treatments and current therapies available for endometrial tumors. Areas covered: This article reviews the current conventional therapies and discusses novel therapeutic agents, some of which are available to clinicians while others are currently being investigated in the preclinical setting. Expert opinion: Genomic and immunohistochemical characterization of endometrial cancer may soon be the best approach for the identification of aggressive forms of tumor. Targeted therapies will soon be standard in the management of endometrial cancer.
引用
收藏
页码：489 / 499
页数：11
相关论文
共 148 条
[31]  
Burke WM, 2014, GYNECOL ONCOL, V134, P393, DOI 10.1016/j.ygyno.2014.06.003
[32]   HER2/neu in Endometrial Cancer A Promising Therapeutic Target With Diagnostic Challenges [J].
Buza, Natalia ;
Roque, Dana M. ;
Santin, Alessandro D. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (03) :343-350
[33]   Uterine carcinosarcoma: A review of the literature [J].
Cantrell, Leigh A. ;
Blank, Stephanie V. ;
Duska, Linda R. .
GYNECOLOGIC ONCOLOGY, 2015, 137 (03) :581-588
[34]   DJ-1 as a human oncogene and potential therapeutic target [J].
Cao, Ji ;
Lou, Siyue ;
Ying, Meidan ;
Yang, Bo .
BIOCHEMICAL PHARMACOLOGY, 2015, 93 (03) :241-250
[35]   Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes [J].
Cardozo, Timothy ;
Pagano, Michele .
BMC BIOCHEMISTRY, 2007, 8
[36]   AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity [J].
Chresta, Christine M. ;
Davies, Barry R. ;
Hickson, Ian ;
Harding, Tom ;
Cosulich, Sabina ;
Critchlow, Susan E. ;
Vincent, John P. ;
Ellston, Rebecca ;
Jones, Darren ;
Sini, Patrizia ;
James, Dominic ;
Howard, Zoe ;
Dudley, Phillippa ;
Hughes, Gareth ;
Smith, Lisa ;
Maguire, Sharon ;
Hummersone, Marc ;
Malagu, Karine ;
Menear, Keith ;
Jenkins, Richard ;
Jacobsen, Matt ;
Smith, Graeme C. M. ;
Guichard, Sylvie ;
Pass, Martin .
CANCER RESEARCH, 2010, 70 (01) :288-298
[37]   The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy [J].
Chu, Isabel M. ;
Hengst, Ludger ;
Slingerland, Joyce M. .
NATURE REVIEWS CANCER, 2008, 8 (04) :253-267
[38]   Results obtained by the use of radium in the treatment of cancer of the uterus - At the University of Pennsylvania Hospital [J].
Clark, JG .
ANNALS OF SURGERY, 1916, 64 :602-612
[39]  
Cohen C J, 1967, Clin Obstet Gynecol, V10, P625, DOI 10.1097/00003081-196709000-00014
[40]   Management of ovarian stromal cell tumors [J].
Colombo, Nicoletta ;
Parma, Gabriella ;
Zanagnolo, Vanna ;
Insinga, Alessandra .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) :2944-2951
12345678910